Affiliation:
1. 1st Cardiology Clinic, ‘Hippokration’ General Hospital, School of Medicine, National and Kapodistrian
University of Athens, Athens, Greece
2. RDM Division of Cardiovascular Medicine, University of Oxford, Oxford,
UK
Abstract
Background:
Chronic low-grade inflammation is involved in coronary atherosclerosis
progression whereas recent research efforts suggest that preventative methods should be
tailored to the “residual inflammatory risk”. As such, modalities for the early identification of
the risk have to be investigated.
Methods:
We performed a systematic review and meta-analysis according to the PRISMA
guidelines. Any study that presented the prognostic value of high sensitivity troponin (hs-cTn)
of vascular inflammation in stable patients without known cardiac heart disease was considered
to be potentially eligible. The Medline (PubMed) database was searched up to April 22,
2021. The main endpoint was the difference in c-index (Δ[c-index]) with the use of hs-cTn
for major adverse cardiovascular events (MACEs), cardiovascular and all-cause mortality.
We calculated I2 to test heterogeneity.
Results:
In total, 44 studies and 112,288 stable patients without known coronary heart disease
were included in this meta-analysis. The mean follow-up duration of the whole cohort was 6.8
± 1.1 years. 77,004 (68.5%) of the patients presented at low cardiovascular risk while 35,284
(31.5%) in high. The overall pooled estimate of Δ[c-index] for MACE was 1.4% (95%CI:
0.7-2.1, I2=0%) and for cardiovascular death 1.3% (95%CI: 0.3-2.3, I2=0%). Finally, the overall
pooled estimate of Δ[c-index] for all-cause mortality was 3% (95%CI: 1.9-3.9, I2=86%),
while high heterogeneity was observed between the studies.
Conclusion:
The predictive usefulness of changes in hs-cTn measures in stable individuals
with either high or low cardiovascular risk, demonstrates that assessing vascular inflammation
in addition to clinical risk factors enhances risk prediction for cardiovascular events and allcause
mortality. Further prospective studies are necessary to confirm these findings and assist
clinical decision-making regarding the most optimal prevention strategy.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry